Bausch Health Companies (NYSE:BHC) has initiated a
clinical trial program in Canada evaluating Virazole (ribavirin),
combined with standard support care, in hospitalized COVID-19 patients
with respiratory distress. The study should launch within the next few
weeks.
The company says ribavirin is a synthetic
nucleoside that works by stopping viral replication, so it may be
effective in reducing the severity of COVID-19. It is currently approved
in Canada, the U.S. and certain other countries for hospitalized
pediatric patients with severe lower respiratory tract infections due to
RSV (respiratory syncytial virus).
Shares up 1% premarket on light volume.
https://seekingalpha.com/news/3560039-bausch-health-launches-study-of-virazole-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.